Bristol-Myers
Squibb Company (NYSE:BMY) today announced that the U.S. Court of
Appeals for the Federal Circuit has denied the company’s appeal of a
February 2013 ruling by the U.S. District Court for the District of
Delaware that found the patent covering Baraclude (entecavir),
U.S. patent 5,206,244 invalid.
The company is reviewing the decision and considering all its legal
options.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers SquibbMediaFrederick Egenolf, 609-252-4875frederick.egenolf@bms.comorInvestor RelationsRyan Asay, 609-252-5020ryan.asay@bms.comRanya Dajani, 609-252-5330ranya.dajani@bms.com